ReviewTranslational pediatrics2026
Biomarkers of partial remission in paediatric type 1 diabetes: β-cell stress, immune-metabolic remodelling, and translational priorities-a narrative review.
Review in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Partial remission after diagnosis of paediatric type 1 diabetes (T1D) is characterised by improved glycaemic control, lower insulin requirements and residual endogenous insulin secretion, but its onset, depth and duration vary substantially between children. Standard clinical indices such as HbA1c, insulin dose-adjusted HbA1c (IDAA1c), C-peptide and continuous glucose monitoring (CGM) metrics capture functional status but provide limited mechanistic information. This narrative review summarises candidate biomarkers that may explain heterogeneity in partial remission and support remission-focused translational studies. Methods: PubMed, Embase, Web of Science and the Cochrane Library were searched for English-language articles published from 1 January 2000 to 31 October 2025. Priority was given to paediatric and adolescent studies, longitudinal cohorts spanning diagnosis and the first year after onset, and studies addressing partial remission, IDAA1c or early C-peptide decline. Mixed-age/adult cohorts and experimental studies were included selectively when they informed biological interpretation. Key Content and Findings: Candidate biomarkers can be organised into two intersecting axes: a β-cell axis reflecting stress, dysfunction and death, and an immune-metabolic axis reflecting immune regulation, inflammatory activity and systemic metabolic adaptation. The proinsulin-to-C-peptide ratio, unmethylated INS-derived cell-free DNA, selected circulating or extracellular vesicle-associated microRNAs, immune-cell phenotypes, soluble mediators and compact omics-derived signatures have varying levels of paediatric evidence. These biomarkers are best interpreted as mechanistic complements to IDAA1c, C-peptide and CGM metrics rather than as replacements for established functional endpoints. Across biomarker classes, associations are modest, assay methods are heterogeneous and external validation remains limited. Conclusions: No single biomarker is currently ready for routine clinical staging of partial remission in paediatric T1D. The most realistic translational path is prospective validation of standardised, parsimonious biomarker panels interpreted alongside IDAA1c, C-peptide and CGM endpoints to improve risk stratification, endotype enrichment and pharmacodynamic monitoring in remission-focused trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.